<2> Convatec FY25 Shares Jump 8% on Growth Target Raise Despite $72 Mln Writedown
<3> Convatec, a leading global medical products and technologies company, has seen its FY25 shares jump 8% following the announcement of a growth target raise despite a $72 million writedown. This significant increase in share value is a testament to the company’s resilience and adaptability in the face of industry challenges.
Bloomberg reports that Convatec’s shares rose to their highest level in over a year, surpassing analyst expectations. The company’s growth target raise is a promising sign for investors, indicating a potential increase in revenue and profitability.
Reuters notes that Convatec’s writedown is largely due to the company’s decision to exit certain underperforming businesses. This strategic move is expected to help the company focus on its core products and services, leading to improved efficiency and profitability.
CNBC reports that Convatec’s growth target raise is driven by the company’s strong